Loading…
Akari Therapeutics, Plc is projected to rise to $18.41 by 2027, a +16% move from its current price of $15.93. AKTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.27 | $15.93 | $17.77 | 0.00% |
| May 30 | $13.64 | $15.93 | $18.59 | +0.01% |
| May 31 | $13.18 | $15.93 | $19.25 | +0.01% |
| Jun 1 | $12.80 | $15.93 | $19.83 | +0.02% |
| Jun 2 | $12.47 | $15.93 | $20.35 | +0.02% |
| Jun 3 | $12.18 | $15.93 | $20.83 | +0.03% |
| Jun 4 | $11.92 | $15.93 | $21.28 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.92 | $15.93 | $21.28 | +0.03% |
| Week 2 | $10.58 | $15.93 | $24.00 | +0.06% |
| Week 3 | $9.65 | $15.94 | $26.32 | +0.09% |
| Week 4 | $8.93 | $15.94 | $28.45 | +0.12% |
| Week 5 | $8.35 | $15.95 | $30.48 | +0.15% |
| Week 6 | $7.85 | $15.95 | $32.43 | +0.18% |
| Week 7 | $7.42 | $15.96 | $34.34 | +0.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Akari Therapeutics, Plc is an oncology company that develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is categorized in Healthcare and operates as a pharmaceutical and biotechnology enterprise within the oncology space.
Akari Therapeutics, Plc trades under the AKTX symbol with a current price of $15.93 and a market cap of $18.23M, ranking 4931 by market capitalization.
The stock’s near-term technical backdrop is NEUTRAL, with RSI (14) at 70, SMA50 at $5.79 and SMA200 at $17.75, and a defined price structure with support at $3.06 and resistance at $18.27. The 30-day price corridor runs from $7.74 to $32.77, highlighting substantial short-term volatility.
Annualized volatility sits at 200%, underscoring the high-risk, high-variance nature of this equity. Forecasts show a path of fluctuating price expectations through 2026–2050, starting with a 2026 average price of $15.93 and moving to later years with notable bullish milestones, including a 2040 average of $29.84 and a 2050 average of $40.99.
A major floor 80.8% below — a decisive break under it would weaken the trend.
The nearest floor, 80.8% below — buyers have tended to step in here.
The nearest ceiling, 14.7% above — a clean break opens room to run.
A major ceiling 73.5% above — clearing it would confirm fresh momentum.
Key AKTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.12 | Buy | $13.20 | Buy |
| MA 10 | $7.82 | Buy | $10.09 | Buy |
| MA 20 | $6.64 | Buy | $7.89 | Buy |
| MA 50 | $5.79 | Buy | $7.11 | Buy |
| MA 100 | $7.97 | Buy | $9.68 | Buy |
| MA 200 | $17.75 | Sell | $18.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 74.09 | Sell |
| Stoch RSI (14) | 81.05 | Sell |
| CCI (20) | 192.93 | Buy |
| Williams %R (14) | -15.42 | Info |
| MACD (12,26,9) | 1.52 | Buy |
| ROC (12) | 154.80 | Buy |
| Bollinger %B (20,2) | 1.00 | Sell |
| Stochastic %K (14) | 84.58 | Sell |
| TRIX (15) | 1.14 | Buy |
| Awesome (5,34) | 6.07 | Buy |
| Ultimate (7,14,28) | 79.26 | Sell |
| Momentum (10) | 12.87 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 18.76 | Sell |
| ADX (14) | 27.56 | Buy |
| ATR (14) | 1.37 | Info |
The 30-day picture is NEUTRAL overall. RSI (14) is 70, suggesting relatively elevated buying pressure but not extreme.
SMA50 is $5.79 and SMA200 is $17.75, indicating short- and longer-term moving averages that are relatively wide apart. The price faces support at $3.06 and resistance at $18.27, framing the near-term range. The recorded 30-day price range spans $7.74 to $32.77, reflecting notable volatility in the compact window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.06 | $15.93 | $25.20 | 0% | Neutral | |
| $13.25 | $18.41 | $27.69 | +16% | Neutral | |
| $10.01 | $14.76 | $23.59 | -7% | Neutral | |
| $10.24 | $15.90 | $26.65 | 0% | Neutral | |
| $8.98 | $14.60 | $25.45 | -8% | Neutral | |
| $8.54 | $14.51 | $26.18 | -9% | Neutral | |
| $11.25 | $19.93 | $37.05 | +25% | Bullish | |
| $11.82 | $21.81 | $41.66 | +37% | Bullish | |
| $11.79 | $22.64 | $44.31 | +42% | Bullish | |
| $10.54 | $21.03 | $42.12 | +32% | Bullish | |
| $13.43 | $29.84 | $65.64 | +87% | Bullish | |
| $18.45 | $40.99 | $94.28 | +157% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.06 | $15.93 | $19.09 | +0.00% |
| June 2026 | $13.86 | $16.62 | $20.65 | +4.37% |
| July 2026 | $13.11 | $15.99 | $20.37 | -3.82% |
| August 2026 | $13.23 | $16.36 | $21.25 | +2.33% |
| September 2026 | $14.17 | $17.71 | $23.38 | +8.30% |
| October 2026 | $14.20 | $17.93 | $23.99 | +1.21% |
| November 2026 | $13.80 | $17.58 | $23.81 | -1.94% |
| December 2026 | $14.31 | $18.39 | $25.20 | +4.61% |
Click any year to see its month-by-month AKTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Akari Therapeutics, Plc's 2026 outlook centres on $15.93, within a $3.06 to $25.20 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AKTX could reach as high as $27.69, with a base case around $18.41 and support toward $13.25 — roughly +16% from $15.93. Price action looks broadly range-bound.
Expect AKTX to range from $10.01 to $23.59 through 2028. The $14.76 average target implies a -7% move from current prices. That is -20% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The AKTX price prediction for 2029 points to an average of $15.90 (low $10.24, high $26.65) — a potential decline of 0% on today's $15.93. Price action looks broadly range-bound.
In 2030, AKTX is projected to trade between $8.98 and $25.45, averaging $14.60 — a potential decline of -8% from today's $15.93. That is -8% versus the projected 2029 average. A consolidation phase looks the most probable path here.
Akari Therapeutics, Plc's 2031 outlook centres on $14.51, within a $8.54 to $26.18 range. That is -1% versus the projected 2030 average. That marks a -9% change versus current levels. Price action looks broadly range-bound.
By 2032, AKTX could reach as high as $37.05, with a base case around $19.93 and support toward $11.25 — roughly +25% from $15.93. Buyers look set to stay in control over this stretch.
Expect AKTX to range from $11.82 to $41.66 through 2033. The $21.81 average target implies a +37% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The AKTX price prediction for 2034 points to an average of $22.64 (low $11.79, high $44.31) — a potential gain of +42% on today's $15.93. Buyers look set to stay in control over this stretch.
In 2035, AKTX is projected to trade between $10.54 and $42.12, averaging $21.03 — a potential gain of +32% from today's $15.93. That is -7% versus the projected 2034 average. Momentum favours further upside here.
Akari Therapeutics, Plc's 2040 outlook centres on $29.84, within a $13.43 to $65.64 range. That is up +42% on the projected 2035 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AKTX could reach as high as $94.28, with a base case around $40.99 and support toward $18.45 — roughly +157% from $15.93. Momentum favours further upside here.
Investing $1,000 in AKTX today (≈ 62.794349 AKTX) could be worth
$2,574.03
+$1,574.03 (+157%) by 2050 · US Dollar
Based on the average projected AKTX price of $40.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKTXwould be worth at today's price.
$1,000 invested in AKTX on May 27, 2025 (≈ 19.841269 AKTX) would be worth
$315.97
-$684.03 (-68.4%) today · 0.32× · US Dollar
Based on a AKTX entry price of $50.4 vs. today's $15.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.43 | $4,642.86 | +364.3% |
| 1 month ago | $5.6 | $2,843.75 | +184.4% |
| 3 months ago | $10.36 | $1,537.16 | +53.7% |
| 6 months ago | $19.44 | $819.19 | -18.1% |
| 1 year ago | $50.4 | $315.97 | -68.4% |
| All time (5.0y) ago | $1,408 | $11.31 | -98.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKTX forecast.
Our base-case forecast reaches $32.00 around 2050.
Implied market cap at $32.00: $36.63M
The multi-year forecast presents a mixed but increasingly bullish trajectory after the early years. The 2026 forecast shows a min of $3.06, an avg of $15.93, and a max of $25.20 with ROI of 0% and NEUTRAL sentiment. By 2022–2029 the path includes several negative ROI years (e.g., 2028 -7.3%, 2029 -0.2%, 2030 -8.3%, 2031 -8.9%), underscoring risk alongside volatility.
Starting in 2032 the outlook turns more constructive, with an avg of $19.93 and a max of $37.05 and ROI of 25.2% (sentiment BULLISH). The bullish cadence continues through 2033 (avg $21.81, max $41.66, ROI 37) and 2034 (avg $22.64, max $44.31, ROI 42.1), then 2035 (avg $21.03, max $42.12, ROI 32.1).
The forecast then accelerates into the 2040s, with 2040 expected to average $29.84 and max $65.64, ROI 87.4, and sentiment BULLISH. By 2050, the avg is projected to $40.99 with a max of $94.28 and ROI 157.4, continuing the bullish stance. These are estimates and not guarantees, and actual results may vary widely given the substantial volatility evident in the data.
Tap a question to reveal the answer.
Min: $8.98, Avg: $14.60, Max: $25.45; ROI: -8.3%; Sentiment: NEUTRAL.
Forecast shows a mix of NEUTRAL years early on (e.g., 2026 avg $15.93, ROI 0) and later bullish years (e.g., 2040 avg $29.84, ROI 87.4; 2050 avg $40.99, ROI 157.4). Several early years also show negative ROI (e.g., 2028 -7.3%, 2030 -8.3%, 2031 -8.9%). The outlook suggests higher potential in the long term but with meaningful risk.
Yes. The forecast max values include $37.05 in 2032 and $41.66 in 2033, with higher ceilings later such as $65.64 in 2040 and $94.28 in 2050.
Low: $7.74, High: $32.77.
Current price: $15.93; Market cap: $18.23M.
Akari Therapeutics, Plc Community Discussion
0Share your Akari Therapeutics, Plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.